Telix Pharmaceuticals - Public Comps and Valuation Multiples

Telix Pharmaceuticals Overview

About Telix Pharmaceuticals

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Founded

2017

HQ

Employees

1K+

Website

telixpharma.com

Sectors

Medical Imaging & Diagnostics
Drug Development & Therapeutics
BioTech
HealthTech

Financials

LTM Revenue $746M

LTM EBITDA $46.1M

EV

$3.8B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Telix Pharmaceuticals Financials

As of September 2025, Telix Pharmaceuticals reported last 12-month revenue of $746M and EBITDA of $46.1M.

In the same period, Telix Pharmaceuticals generated $438M in LTM gross profit and $19.7M in net income.

See Telix Pharmaceuticals valuation multiples based on analyst estimates

Telix Pharmaceuticals P&L

In the most recent fiscal year, Telix Pharmaceuticals reported revenue of $317M and EBITDA of $37.5M.

Telix Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Telix Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$746M	XXX	$317M	XXX	XXX	XXX
Gross Profit	$438M	XXX	$206M	XXX	XXX	XXX
Gross Margin	59%	XXX	65%	XXX	XXX	XXX
EBITDA	$46.1M	XXX	$37.5M	XXX	XXX	XXX
EBITDA Margin	6%	XXX	12%	XXX	XXX	XXX
EBIT	$42.7M	XXX	$33.0M	XXX	XXX	XXX
EBIT Margin	6%	XXX	10%	XXX	XXX	XXX
Net Profit	$19.7M	XXX	$20.2M	XXX	XXX	XXX
Net Margin	3%	XXX	6%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Telix Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $746M. EBITDA for the last twelve months was $46.1M. In the most recent fiscal year, Telix Pharmaceuticals achieved $317M in revenue and $37.5M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$746M	Analyst estimates available to subscribers	$317M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$438M	Analyst estimates available to subscribers	$206M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	58.7% gross margin	Analyst estimates available to subscribers	65.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$46.1M	Analyst estimates available to subscribers	$37.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	6.2% EBITDA margin	Analyst estimates available to subscribers	11.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$42.7M	Analyst estimates available to subscribers	$33.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	5.7% EBIT margin	Analyst estimates available to subscribers	10.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$19.7M	Analyst estimates available to subscribers	$20.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	2.6% net profit margin	Analyst estimates available to subscribers	6.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Telix Pharmaceuticals

This financial data table provides comprehensive performance metrics for Telix Pharmaceuticals, a company based in Australia. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Telix Pharmaceuticals generated $746M in revenue over the last twelve months.
The company achieved $46.1M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $438M.
Net income over the last twelve months reached $19.7M.

Fiscal Year Performance

In the most recent fiscal year, Telix Pharmaceuticals reported $317M in total revenue.
Fiscal year EBITDA was $37.5M.
The company maintained a gross profit margin of 65.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 11.8%.
Net profit margin reached 6.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Telix Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Telix Pharmaceuticals Stock Performance

Telix Pharmaceuticals has current market cap of AUD 5.6B (or $3.6B), and EV of AUD 5.9B (or $3.8B).

Market Cap Evolution

Telix Pharmaceuticals Stock Data

As of October 17, 2025, Telix Pharmaceuticals's stock price is AUD 17 (or $11).

See Telix Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.8B	$3.6B	XXX	XXX	XXX	XXX	$0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Telix Pharmaceuticals Valuation Multiples

Telix Pharmaceuticals's trades at 12.1x EV/Revenue multiple, and 102.5x EV/EBITDA.

See valuation multiples for Telix Pharmaceuticals and 15K+ public comps

Telix Pharmaceuticals Financial Valuation Multiples

As of October 17, 2025, Telix Pharmaceuticals has market cap of $3.6B and EV of $3.8B.

Equity research analysts estimate Telix Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Telix Pharmaceuticals has a P/E ratio of 184.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$3.6B	XXX	$3.6B	XXX	XXX	XXX
EV (current)	$3.8B	XXX	$3.8B	XXX	XXX	XXX
EV/Revenue	5.1x	XXX	12.1x	XXX	XXX	XXX
EV/EBITDA	83.3x	XXX	102.5x	XXX	XXX	XXX
EV/EBIT	89.9x	XXX	116.4x	XXX	XXX	XXX
EV/Gross Profit	8.8x	XXX	n/a	XXX	XXX	XXX
P/E	184.6x	XXX	179.5x	XXX	XXX	XXX
EV/FCF	-43.0x	XXX	1054.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Telix Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Telix Pharmaceuticals Margins & Growth Rates

Telix Pharmaceuticals's last 12 month revenue growth is 22%

Telix Pharmaceuticals's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Telix Pharmaceuticals's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Telix Pharmaceuticals's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Telix Pharmaceuticals and other 15K+ public comps

Telix Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	22%	XXX	72%	XXX	XXX	XXX
EBITDA Margin	6%	XXX	12%	XXX	XXX	XXX
EBITDA Growth	26%	XXX	130%	XXX	XXX	XXX
Rule of 40	26%	XXX	34%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	62%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	15%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	25%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	55%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial